Characterization of patients with ovarian cancer. Gyneco-obstetric Hospital “Ramón González Coro” 2001-2013

Authors

  • Yosmira Brito Domínguez Hospital Ginecobstétrico Ramón González Coro. La Habana.
  • Frank Caravia Bernaldo Hospital Universitario Ginecobstétrico Eusebio Hernádez. La Habana.
  • Daisy Hernández Durán Hospital Ginecobstétrico Ramón González Coro. La Habana.
  • Aida Gisela González Aguiar Policlínico Universitario La Rampa. La Habana.
  • Juliette Massip Nicot Hospital Universitario Clínico Quirúrgico General Calixto García. La Habana.

Keywords:

ovarian cancer, Gynecology, Oncology.

Abstract

Background: currently in Cuba and around the world, the ovarian cancer represents the eighth most important cause of malignant neoplasia in women, but it is the fourth cause related with mortality.
Objective:  identifying behavior by histological types and by ovarian cancer treatment.

Materials and methods:  a descriptive, retrospective study was carried out in patients with ovarian cancer attended in the Hospital “Ramón González Coro”, Havana, in the period between January 2001 and July 2013. The analysis units were the clinical records of the 98 studied patients.
Outcomes: it was observed that 69.3 % were aged 31-60 years. The average age of the entire group was 48.2 years; half of the patients did not refer pathological antecedents. The average parity was 1.3. 3.1 % had antecedents of confirmed and treated malignant neoplasia; 14.3 % had maternal antecedents of malignant neoplasia, being the most frequent motive of consultation “pain in the low womb” (40.8 %). There was not significant association between the stages (FIGO) and the cancer type.
Conclusions: the obtained results behave, in general, according to the epidemiological patterns internationally reported, though the frequency of the epithelial cancer was lower than the one referred in the consulted literature. Most of the studied cancers were in stages I and III.


Downloads

Download data is not yet available.

References

Bibliografía
1. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011 Dec [citado 2015 Jul 09];32(6):1087-95. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21863264
2. OMS. Mujeres, niñas y adolescentes. Igualdad de oportunidades para necesidades diferentes. 2012. [citado 12 de junio del 2015] Disponible en:http://www.humanitarianreform.org/humanitarianreform/Portals/1/cluster%20approach%20page/clusters%20pages/Gender/Gender%20Toolkit/Spanish%20Web_full%20w%20covers.pdf
3. MINSAP. Anuario Estadístico de Salud. 2014. Dirección Nacional de Estadísticas. República de Cuba. La Habana: 2015. [citado 20 Jun 2015] Disponible en: http://www.sld.cu/galerias/pdf/sitios/dne/anuario_2014_3e.pdf
4. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, et al. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Jun [citado 2015 Jul 09]; 23(5):815-22. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23669443
5. Zhang YJ, Cao LY, Fu ZZ, Wang YJ, Wang GX, Gu T. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer. J Cancer Res Ther. 2015 Apr-Jun;11(2):375-80.
6. Wang Q, Bian CE, Peng H, He L, Zhao X. Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis. Mol Clin Oncol. 2015 May [citado 2015 Jul 09]; 3(3):623-628. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26137278
7. Huang ZP, Liu XJ, Zou BX, Shen Q, Liu Y, Zhou T. Ovarian cancer transformation from adenocarcinoma to undifferentiated small cell carcinoma: A case report. Oncol Lett. 2015 May [citado 2015 Jul 09]; 9(5):2230-2232. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26137046
8. Villegas Valverde CA, Arango Prado MC. Participación de los linfocitos T reguladores en el cáncer de ovario. Rev Cubana Obstet Ginecol [revista en la Internet]. 2013 Mar [citado 2015 Jul 09] ; 39(1): 23-32. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2013000100004&lng=es
9. Abu Hassan SO, Petersen PH, Lund F, Nielsen DL, Tuxen MK, Sölétormos G. Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation. Biomark Med. 2015 Jul 6:1-12.
10. Clavijo Rodríguez T, Lugones Botell M, Guevara Alfayate L, Berlán León N. Aspectos clínicos y epidemiológicos de los tumores anexiales. Rev Cubana Obstet Ginecol [revista en la Internet]. 2012 Jun [citado 2015 Jul 09] ; 38(2): 221-228. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2012000200009&lng=es.
11. Pons Porrata LM, García Gómez O, Salmon Cruzata A, Macías Navarro MM, Guerrero Fernández CM. Tumores de ovario: patogenia, cuadro clínico, diagnóstico ecográfico e histopatológico. MEDISAN [revista en la Internet]. 2012 Jun [citado 2015 Jul 09] ; 16(6): 920-931. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192012000600013&lng=es
12. Jeong HH, Leem S, Wee K, Sohn KA. Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer. J Ovarian Res. 2015 Jul 3 [citado 2015 Jul 09]; 8(1):42. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26138921
13. Báez Pupo F, Díaz Brito Y, Báez Pupo María M. Diagnóstico ultrasonográfico de las masas pélvicas ginecológicas. Rev Cubana Obstet Ginecol [revista en la Internet]. 2014 Dic [citado 2015 Jul 09] ; 40(4): 378-387. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2014000400004&lng=es.
14. Hogg SJ, Evans JJ, Sykes PH, Chitcholtan K. A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. J Ovarian Res. 2015 Jul 4[citado 2015 Jul 09]; 8(1):43. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26141064
15. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014 Sep;134(3):455-61.
16. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M; Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011 Feb;21(2):419-23.
17. Steffensen KD, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012 Nov [citado 2015 Jul 09]; 22(9):1474-82. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23095772
18. Bacalbasa N, Dima S, Balescu I, David L, Brasoveanu V, Popescu I. Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience. Anticancer Res. 2015 Jul;35(7):4099-104.
19. Lu Y, Huang S, Li P, Chen B, Liu W, Chen Z, Yin F. Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer. Exp Ther Med. 2015 May [citado 2015 Jul 09]; 9(5):2003-2007. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26136929
20. Huang R, Wang J, Zhong Y, Liu Y, Stokke T, Trope CG, Nesland JM, Suo Z. Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties. Anticancer Res. 2015 Jul [citado 2015 Jul 09]; 35(7):3743-53. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26124317
21. Valladares M, Corsini G, Romero C. Asociación entre obesidad y cáncer de ovario. Rev. méd. Chile mayo 2014 [citado 2015 Jul 09]; 142(5): Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000500007&lang=pt
22. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS; PLCO Project Team. Ovarian cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18 [citado 2015 Jul 09]; 104(2):125-32. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22228146

Downloads

Published

2017-07-12

How to Cite

1.
Brito Domínguez Y, Caravia Bernaldo F, Hernández Durán D, González Aguiar AG, Massip Nicot J. Characterization of patients with ovarian cancer. Gyneco-obstetric Hospital “Ramón González Coro” 2001-2013. Rev Méd Electrón [Internet]. 2017 Jul. 12 [cited 2025 Jan. 24];39:729-40. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/1645

Issue

Vol. 39 (2017): Suplemento 1

Section

Research article

License

All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.

It allows:

 - Copy and redistribute published material in any medium or format.

 - Adapt the content.

 This will be done under the following terms:

 - Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.

 - Non-commercial use.

 - Recognize the journal where it is published.

 The copyrights of each article are maintained, without restrictions.

Most read articles by the same author(s)